The Extraordinary General Meeting 2022 of RaySearch Laboratories AB (publ) was held only through postal voting in accordance with temporary legislation. The following resolutions were adopted.
The Extraordinary General Meeting resolved that the number of Board members be five, with no deputies, and elected Günther Mårder as new Board member for the period until the next Annual General Meeting. The Board of Directors therefore consists of the Board members Carl Filip Bergendal, Johan Löf, Britta Wallgren, Hans Wigzell and Günther Mårder.
Further, the Extraordinary General Meeting resolved on remuneration to the newly elected board member and the Chairman of the Board in accordance with the levels of remuneration resolved by the Annual General Meeting 2022, in proportion to the duration of the term of office.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
Björn Hårdemark, interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 709 564 217